- Home
- POLE vs ELDN Comparison
POLE vs ELDN Comparison
Compare POLE & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLE
- ELDN
- Stock Information
- Founded
- POLE 2024
- ELDN 2004
- Country
- POLE United States
- ELDN United States
- Employees
- POLE N/A
- ELDN N/A
- Industry
- POLE
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- POLE
- ELDN Health Care
- Exchange
- POLE NYSE
- ELDN Nasdaq
- Market Cap
- POLE 296.0M
- ELDN 288.5M
- IPO Year
- POLE 2024
- ELDN N/A
- Fundamental
- Price
- POLE $10.08
- ELDN $4.29
- Analyst Decision
- POLE
- ELDN Strong Buy
- Analyst Count
- POLE 0
- ELDN 1
- Target Price
- POLE N/A
- ELDN $16.00
- AVG Volume (30 Days)
- POLE 3.6K
- ELDN 232.7K
- Earning Date
- POLE 01-01-0001
- ELDN 03-27-2025
- Dividend Yield
- POLE N/A
- ELDN N/A
- EPS Growth
- POLE N/A
- ELDN N/A
- EPS
- POLE N/A
- ELDN N/A
- Revenue
- POLE N/A
- ELDN N/A
- Revenue This Year
- POLE N/A
- ELDN N/A
- Revenue Next Year
- POLE N/A
- ELDN N/A
- P/E Ratio
- POLE N/A
- ELDN N/A
- Revenue Growth
- POLE N/A
- ELDN N/A
- 52 Week Low
- POLE $9.94
- ELDN $1.52
- 52 Week High
- POLE $11.05
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- POLE N/A
- ELDN 44.28
- Support Level
- POLE N/A
- ELDN $4.40
- Resistance Level
- POLE N/A
- ELDN $4.65
- Average True Range (ATR)
- POLE 0.00
- ELDN 0.23
- MACD
- POLE 0.00
- ELDN -0.04
- Stochastic Oscillator
- POLE 0.00
- ELDN 8.16
About POLE ANDRETTI ACQUISITION CORP. II
Andretti Acquisition Corp II is a blank check company.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.